To evaluate the effect of EZH2 inhibition on cisplatin sensitivity, six liver cancer cell lines (HBC108, HBC129, HBC130, HepG2, HUH7, and HUH6) were treated with increasing concentrations of cisplatin (0–400 μM), either alone or in combination with EPZ-6438 (10 μM) or GSK-126 (5 μM). The gene discussed is EZH2; the disease is liver cancer.